查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1888689

美國泛自閉症障礙治療市場規模、佔有率和趨勢分析報告：按治療類型、應用、分銷管道和細分市場預測（2025-2033 年）

U.S. Autism Spectrum Disorder Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Application, By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國泛自閉症障礙治療市場摘要

2024年美國泛自閉症障礙治療市場規模估計為8.2784億美元，預計2033年將達到14.316億美元。

預計從 2025 年到 2033 年，該市場將以 6.30% 的複合年成長率成長。診斷率的提高和治療服務的普及正在推動美國泛自閉症障礙(ASD) 治療市場的成長。

看護者、小兒科和教育工作者對自閉症譜系障礙的認知不斷提高，推動了早期篩檢的增加和及時轉診至專科護理。行為療法、藥物療法和數位平台等治療機構正在擴大服務範圍，以滿足日益成長的需求。不斷發展的診斷技術持續支持更精準、更個人化的治療方案，有助於整體治療效果的提升。例如，美國疾病管制與預防中心（CDC）在2025年5月報告稱，每31名8歲兒童中就有1名（3.2%）被診斷患有泛自閉症障礙，並指出該疾病在不同種族、民族和社會經濟群體中均有發生。該機構還指出，自閉症在男孩中的發生率是女孩的三倍多，2009 年至 2017 年間，六分之一（17%）的 3 至 17 歲兒童被診斷患有發育障礙（包括泛自閉症障礙），2022 年的患病率為每 1000 名兒童 32.2 人（31 人中 11 人）。

在美國，藥物研發仍然是泛自閉症障礙治療產業的關鍵驅動力。各公司正致力於研發針對易怒、過動和行為失調等症狀的治療方法。強大的後期開發平臺有望擴大兒童和成人的治療覆蓋範圍。將數位行為療法融入臨床路徑，提高了治療的一致性、擴充性和可近性，尤其對需要遠距介入的家庭而言更是如此。將結構化行為療法與藥物治療結合的實證治療方法，能夠改善患者的功能和社會功能。這些不斷發展的護理模式正在推動不同患者群體接受治療。

對研究、數據驅動技術和跨學科護理的投資持續推動美國市場的發展。先進的分析工具正在加深我們對神經生物學機制的理解，並加速發現新的治療標靶。美國學術機構、臨床網路和產業夥伴之間的緊密合作正在提高臨床試驗的效率和轉化研究的成功率。例如，2025年5月，美國疾病管制與預防中心（CDC）重申，泛自閉症障礙的診斷取決於看護者的發展史以及基於DSM-5標準的行為評估。這些標準包括三個嚴重程度等級：1級（需要支援）、2級（需要大量支援）和3級（需要非常大量的支援）。整合醫療保健、行為療法、教育和數位科技的跨學科照護框架的日益普及，正在幫助美國泛自閉症障礙的治療環境朝著更全面和永續的未來邁進。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章美國泛自閉症障礙治療市場變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章美國泛自閉症障礙治療市場：按治療類型分類的業務分析

  • 按治療類型分類的市場佔有率（2024 年和 2033 年）
  • 按治療類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 抗精神病藥物
  • 選擇性血清素再回收抑制劑
  • 興奮劑
  • 安眠藥
  • 其他

第5章美國泛自閉症障礙治療市場：按應用領域分類的業務分析

  • 按應用領域分類的市場佔有率（2024 年和 2033 年）
  • 按應用領域分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 泛自閉症障礙
  • 亞斯伯格症候群
  • 廣泛性發展障礙
  • 其他

第6章美國泛自閉症障礙治療市場：按通路分類的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 競爭情勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Johnson &Johnson（Janssen）
    • Roche（F. Hoffmann-La Roche）
    • Otsuka Pharmaceutical Co., Ltd.
    • AbbVie Inc.
    • Novartis AG
    • Eli Lilly &Company
    • Curemark LLC
    • Yamo Pharmaceuticals
    • PaxMedica
    • Merck &Co., Inc.
Product Code: GVR-4-68040-817-7

U.S. Autism Spectrum Disorder Treatment Market Summary

The U.S. autism spectrum disorder treatment market size was estimated at USD 827.84 million in 2024 and is projected to reach USD 1,431.60 million by 2033, growing at a CAGR of 6.30% from 2025 to 2033. The increasing diagnosis rates and wider access to therapeutic services drive the growth of the Autism Spectrum Disorder (ASD) treatment market in the U.S.

Growing awareness among caregivers, pediatricians, and educators has led to increased early screening and expedited referrals to specialized care. Treatment providers across behavioral therapy, pharmacologic care, and digital platforms are broadening their service footprint to meet the rising demand. Diagnostic refinement continues to support more precise and individualized care pathways, thereby improving overall treatment outcomes. For instance, in May 2025, the Centers for Disease Control and Prevention reported that 1 in 31 children aged 8 years (3.2%) had been identified with autism spectrum disorder, noting occurrence across all racial, ethnic, and socioeconomic groups. The agency further stated that autism was more than three times more common in boys than in girls and that 1 in 6 children aged 3-17 years (17%) had been diagnosed with a developmental disability-including autism spectrum disorder-between 2009 and 2017, with 2022 prevalence at 32.2 per 1,000 children (1 in 31).

Pharmaceutical development remains a central growth driver for the U.S. autism spectrum disorder treatment industry, as the companies focus on therapies addressing irritability, hyperactivity, and behavioral dysregulation. A robust late-stage pipeline is expected to expand treatment eligibility across both pediatric and adult populations. The integration of digital behavioral therapies into clinical pathways is enhancing consistency, scalability, and accessibility, particularly for families requiring remote interventions. Evidence-based treatment combinations, including structured behavioral programs paired with pharmacologic support, strengthen functional and social outcomes. These evolving care models are increasing the adoption of treatment across diverse patient segments.

Investment in research, data-driven technologies, and multidisciplinary care continues to shape the U.S. market's progress. Advanced analytic tools are deepening the understanding of neurobiological mechanisms, accelerating the discovery of new therapeutic targets. Strong collaboration between U.S. academic centers, clinical networks, and industry partners is enhancing trial efficiency and translational success. For instance, in May 2025, the Centers for Disease Control and Prevention reiterated that autism spectrum disorder diagnosis relies on caregiver developmental histories and behavioral assessments guided by DSM-5 criteria, which include three severity levels, namely, Level 1 requiring support, Level 2 requiring substantial support, and Level 3 requiring very substantial support. The growing use of multidisciplinary care frameworks, combining medical, behavioral, educational, and digital components, continues to reinforce a more holistic and sustainable U.S. Autism Spectrum Disorder treatment landscape.

U.S. Autism Spectrum Disorder Treatment Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. autism spectrum disorder treatment market report based on treatment type, application, and distribution channel:

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Antipsychotic Drugs
  • Selective Serotonin Reuptake Inhibitors
  • Stimulants
  • Sleep Medications
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive Developmental Disorder
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment Type
    • 1.2.2. Application
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Autism Spectrum Disorder Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Autism Spectrum Disorder Treatment Market: Treatment Type Business Analysis

  • 4.1. Treatment Type Market Share, 2024 & 2033
  • 4.2. Treatment Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
  • 4.4. Antipsychotic Drugs
    • 4.4.1. Antipsychotic Drugs Market, 2021 - 2033 (USD Million)
  • 4.5. Selective Serotonin Reuptake Inhibitors
    • 4.5.1. Selective Serotonin Reuptake Inhibitors Market, 2021 - 2033 (USD Million)
  • 4.6. Stimulants
    • 4.6.1. Stimulants Market, 2021 - 2033 (USD Million)
  • 4.7. Sleep Medications
    • 4.7.1. Sleep Medications Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Autism Spectrum Disorder Treatment Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2033
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Autistic Disorder
    • 5.4.1. Autistic Disorder Market, 2021 - 2033 (USD Million)
  • 5.5. Asperger Syndrome
    • 5.5.1. Asperger Syndrome Market, 2021 - 2033 (USD Million)
  • 5.6. Pervasive Developmental Disorder
    • 5.6.1. Pervasive Developmental Disorder Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Autism Spectrum Disorder Treatment Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacy
    • 6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Johnson & Johnson (Janssen)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Roche (F. Hoffmann-La Roche)
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Otsuka Pharmaceutical Co., Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. AbbVie Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Novartis AG
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Eli Lilly & Company
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Curemark LLC
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Yamo Pharmaceuticals
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. PaxMedica
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Merck & Co., Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 US autism spectrum disorder treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 4 US autism spectrum disorder treatment market, by application, 2021 - 2033 (USD Million)
  • Table 5 US autism spectrum disorder treatment market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. autism spectrum disorder treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 U.S. autism spectrum disorder treatment market dynamics
  • Fig. 11 U.S. autism spectrum disorder treatment market: Porter's five forces analysis
  • Fig. 12 U.S. autism spectrum disorder treatment market: PESTLE analysis
  • Fig. 13 Treatment Type market, 2021 - 2033 (USD Million)
  • Fig. 14 Antipsychotic Drugs market, 2021 - 2033 (USD Million)
  • Fig. 15 Selective Serotonin Reuptake Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 16 Stimulants market, 2021 - 2033 (USD Million)
  • Fig. 17 Sleep Medications market, 2021 - 2033 (USD Million)
  • Fig. 18 Others market, 2021 - 2033 (USD Million)
  • Fig. 19 Application market, 2021 - 2033 (USD Million)
  • Fig. 20 Autistic Disorder market, 2021 - 2033 (USD Million)
  • Fig. 21 Asperger Syndrome market, 2021 - 2033 (USD Million)
  • Fig. 22 Pervasive Developmental Disorder market, 2021 - 2033 (USD Million)
  • Fig. 23 Others market, 2021 - 2033 (USD Million)
  • Fig. 24 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 25 Hospital Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 26 Retail Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 27 Online Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 28 Company categorization
  • Fig. 29 Company market position analysis
  • Fig. 30 Strategic framework